# FDA Issues Complete Response Letter to Elevar for Rivoceranib Combo in Hepatocellular Carcinoma

> fda · REPORTED · 2026-07-14

The FDA issued a complete response letter to Elevar Therapeutics for its NDA seeking approval of rivoceranib combined with camrelizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, citing manufacturing deficiencies at the drug's production facility.

About Elevar Therapeutics: Elevar Therapeutics is a majority-owned subsidiary of South Korea's HLB Group, focused on developing oncology treatments including angiogenesis inhibitors for liver and other cancers.

- Company: Elevar Therapeutics
- Sector: oncology
- Primary source: https://www.thepharmaletter.com/biotech-news/celcuity-wins-first-fda-approval-with-revtorpyk-in-advanced-breast-cancer

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.